Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
AMED > SEC Filings for AMED > Form 8-K on 27-Mar-2014All Recent SEC Filings

Show all filings for AMEDISYS INC

Form 8-K for AMEDISYS INC


27-Mar-2014

Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State


Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 26, 2014, the Board of Directors (the "Board") of Amedisys, Inc. (the "Company") appointed Nathaniel M. Zilkha to the Board upon the recommendation of the Board's Nominating and Corporate Governance Committee. Mr. Zilkha is a member of the general partner of KKR & Co. L.P. (together with its affiliates, "KKR") and serves as Head of KKR's credit platform and as the Global Co-Head of Special Situations. With this addition, the Company's Board now comprises seven directors. It is intended that Mr. Zilkha will be a nominee for election to the Board at the Company's 2014 Annual Meeting of Stockholders to be held in early June 2014. Contemporaneously with his appointment to the Board, Mr. Zilkha was also appointed to the Audit, Compensation, Compliance and Ethics, Nominating and Corporate Governance and Quality of Care Committees of the Board.

The Company reports that there are no other transactions between the Company or any of its subsidiaries, on the one hand, and Mr. Zilkha and/or KKR, on the other hand, that would require disclosure pursuant to Item 404(a) of Regulation S-K.

As a non-employee director, Mr. Zilkha will receive the Company's standard non-employee director compensation, as described in the Company's 2013 Proxy Statement on Schedule 14A, filed with the United States Securities and Exchange Commission on April 26, 2013. In connection with his service on the Board, the Company and Mr. Zilkha will enter into an Indemnification Agreement, a form of which was previously filed as Exhibit 10.1 to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008.



Item 7.01. Regulation FD Disclosure.

On March 27, 2014, the Company issued a press release titled "Amedisys Expands its Board of Directors with Appointment of KKR's Nathaniel M. Zilkha," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.



Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Press Release dated March 27, 2014 titled "Amedisys Expands its Board of Directors with Appointment of KKR's Nathaniel M. Zilkha" (furnished only)


  Add AMED to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for AMED - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.